← Research library

Myasthenia gravis reported after repeated thymopentin courses

Letter or commentary · 2026

What was studied
One 75-year-old woman with persistent lymphopenia after treatment for triple-negative breast cancer.
What the source reports
Clinical course · Eyelid drooping first appeared after an October 2023 course. Chewing weakness and later neck weakness and dysphagia were reported after subsequent courses. Acetylcholine receptor antibody titer was 1:100.

Reported findings and study design

Reported findings

Thymopentin was given at 10 mg every other day for 14 doses per course, with courses every six months beginning in 2019. The report does not specify the administration route.

Population or model One 75-year-old woman with persistent lymphopenia after treatment for triple-negative breast cancer.

Dose, route and schedule

Thymopentin was given at 10 mg every other day for 14 doses per course, with courses every six months beginning in 2019. The report does not specify the administration route.

Protocol source ↗ · Original case report, including clinical timeline and electrophysiology table.

Results · Original case report, including clinical timeline and electrophysiology table.
MeasureResultComparison, timing and statistics
Clinical courseEyelid drooping first appeared after an October 2023 course. Chewing weakness and later neck weakness and dysphagia were reported after subsequent courses. Acetylcholine receptor antibody titer was 1:100.
Myasthenia severity after treatmentQuantitative Myasthenia Gravis score fell from 20 at admission to 10 at discharge and 3 at follow-up after thymopentin was stopped and myasthenia treatment was started.

A single case supplies a temporal association. Prior cancer treatment and concurrent myasthenia therapy limit causal attribution, and incidence cannot be estimated.

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • A single case supplies a temporal association. Prior cancer treatment and concurrent myasthenia therapy limit causal attribution, and incidence cannot be estimated.

Source details

Original case report, including clinical timeline and electrophysiology table.

Sources checked

Added to the library

Citation

Letter / commentaryFull text available

N. Zhao, L. Yang, T. Li. Myasthenia gravis reported after repeated thymopentin courses Balkan Medical Journal 43, 291–293

Study source ↗ · DOI 10.4274/balkanmedj.galenos.2025.2025-10-197 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards